RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody

Flow cytometric analysis of Jurkat cells with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Jurkat cell lysate probed with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Jurkat cell lysate probed with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in N2A cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in N2A cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse testis tissue incubated with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse testis tissue incubated with RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody (bsm-52674R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52674R
Product Name	RUNX1+RUNX2+RUNX3 (1C3) Monoclonal Antibody
Applications	WB FCM IHC-P IF(ICC) IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	C terminus Human RUNX1
Clonality	Monoclonal
Clone #	1C3
Isotype	IgG
Concentration	Lot Dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Swiss Prot	Q01196, Q13761, Q13950
Synonyms	Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, Runt-related transcription factor 2, Acute myeloid leukemia 3 protein, Core-binding factor subunit alpha-1, Oncogene AML-3, Osteoblast-specific transcription factor 2, Polyomavirus enhancer-binding protein 2 alpha A subunit, SL3-3 enhancer factor 1 alpha A subunit, SL3/AKV core-binding factor alpha A subunit, Runt-related transcription factor 3, Acute myeloid leukemia 2 protein, Core-binding factor subunit alpha-3, Oncogene AML-2, Polyomavirus enhancer-binding protein 2 alpha C subunit, SL3-3 enhancer factor 1 alpha C subunit, SL3/AKV core-binding factor alpha C subunit, CBF-alpha-2, PEA2-alpha B, PEBP2-alpha B, RUNX1, CBF-alpha-1, OSF-2, PEA2-alpha A, PEBP2-alpha A, RUNX2, CBF-alpha-3, PEA2-alpha C, PEBP2-alpha C, RUNX3
Background	CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532).
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC